Home
overview

For the latest COVID-19 Travel restrictions and recommendations please click here

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. This is reflected with the value of the global antisense & RNA therapeutics market expected to reach USD 1.81 billion by 2025, growing at a CAGR of 7.5%. Furthermore, the recent advent of CRISPR, an RNA-guided gene-editing technology, as well as new strides in the delivery of messenger RNA transcribed in vitro, have triggered a major expansion of the RNA-therapeutics field.

Part of the SMi’s leading RNA Therapeutics Portfolio, this year will host a preconference focus day to explore and assess the latest advances of vaccines in the RNA industry. Leading industry fi gures will give an insight into the pivotal role of the RNA industry over the past year in the global pandemic, while further case studies will explore the vast therapeutic potential of mRNA-based vaccines. The focus day will open discussion for improved strategies to enhance vaccine development in the industry and industry outlooks will assess the potential of vaccine technology for future infectious diseases.
 

  • Hear from leading industry experts on how the industry has adapted to develop lifesaving COVID-19 vaccine candidates
  • Discover the power of mRNA-based vaccines for cancer therapy
  • Understand the evolving technologies being developed to build the next generation of vaccines
  • Engage in industry outlooks assessing the potential of vaccines in the RNA industry for future infectious diseases

Focus Day programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Steve Pascolo

Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
View Bio

9:10 Synthetic mRNA vaccines

Steve Pascolo

Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
View Bio

  • History of synthetic mRNA vaccines
  • Mode of action of natural and synthetic mRNA vaccines
  • Production and formulation of synthetic mRNA vaccines
  • Vaccines and therapies based on synthetic mRNA: now and in the future 
  • 9:50 Accelerated development of messenger RNA based COVID-19 candidate vaccines

    Arun Kumar

    Arun Kumar, Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
    View Bio

  • The development of mRNA-based vaccines is much faster compared to traditional approaches of vaccines development
  • There are more than 18 vaccines under clinical evaluation and at least 25 under preclinical development
  • mRNA platform technology promises to revolutionize future vaccines
  • CEPI’s current portfolio of mRNA-based vaccines and future directions
  • 10:30 Morning Coffee

    11:00 Innovative mRNA technology for COVID-19 vaccine development

    Sun Woo Hong

    Sun Woo Hong, CEO, mCureX Therapeutics
    View Bio

  • Introducing mCureX mRNA technology
  • Discovery of an mRNA delivery system in a collaborative way
  • Preclinical development of COVID-19 vaccine candidates
  • 11:40 Personalized mRNA vaccine for gastrointestinal cancer patients

    Gal Cafri

    Gal Cafri, Immunotherapy and Genetic Engineering Group leader, Sheba Medical Center
    View Bio

  • Insights from pre-clinical development of personalized mRNA vaccines for cancer patients
  • mRNA vaccine–induced neoantigen-specifi c T cell immunity in patients with gastrointestinal cancer
  • Assessing clinical data from early phase clinical trials
  • The future of mRNA technologies and vaccines in oncology
  • 12:20 Networking Lunch

    13:20 Identification of Frame neoantigens for use in mRNA cancer vaccines

    Wigard Kloosterman

    Wigard Kloosterman, Chief Scientific Officer, Frame Therapeutics
    View Bio

  • A collaboration with eTheRNA Immunotherapies to develop a new generation of mRNA cancer vaccines
  • Highlighting Frame Therapeutics’ workflow to identify novel classes of neoantigens
  • Presentation of immunological readout of Frame mRNA vaccines
  • 14:00 Assessing delivery systems for future mRNA vaccines

    Heinrich Haas

    Heinrich Haas, Vice President Formulation & Drug Delivery, BioNTech
    View Bio

  • An executive overview of delivery systems for mRNA vaccines
  • Conceptual aspects of LNPs and other delivery systems 
  • Current examples of LNP delivery systems for mRNA vaccines
  • Exploring the future of vaccine delivery technologies in the RNA industry
  • 14:40 Afternoon Tea

    15:10 Using optimal technologies to build the next generation of vaccines

    Derek O Hagan

    Derek O Hagan, Senior Advisor, GSK
    View Bio

  • The rapid advance of RNA vaccines
  • The next generation of RNA vaccines
  • Which vaccines can we build next with RNA
  • The future role of vaccine adjuvants
  • 15:50 The potential of mRNA-based vaccines for infectious diseases

    Priya Karmali

    Priya Karmali, Vice President, Technology Innovation and Development, Arcturus Therapeutics
    View Bio

  • An insight into Arcturus’ pipeline of vaccines and mRNA technologies
  • Challenges in large-scale production of mRNA vaccines and how have we seen the industry develop and adapt in the past year
  • Considerations for novel development and manufacturing technologies for mRNA vaccines and lessons learned from the COVID-19 vaccines
  • Future mRNA vaccine development - how can we expect the industry to move forward in this space
  • 16:30 Chairman’s Closing Remarks and Close of Day One

    Steve Pascolo

    Steve Pascolo, Founder and CEO, Miescher Pharma GmbH
    View Bio

    +

    FEATURED SPEAKERS

    Arun Kumar

    Arun Kumar

    Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
    Derek O Hagan

    Derek O Hagan

    Senior Advisor, GSK
    Gal Cafri

    Gal Cafri

    Immunotherapy and Genetic Engineering Group leader, Sheba Medical Center
    Heinrich Haas

    Heinrich Haas

    Vice President Formulation & Drug Delivery, BioNTech
    Priya Karmali

    Priya Karmali

    Vice President, Technology Innovation and Development, Arcturus Therapeutics
    Sun Woo Hong

    Sun Woo Hong

    CEO, mCureX Therapeutics
    Wigard Kloosterman

    Wigard Kloosterman

    Chief Scientific Officer, Frame Therapeutics

    Arun Kumar

    Preclinical Vaccine Development Lead, Coalition for Epidemic Preparedness Innovations (CEPI)
    Arun Kumar

    Dr. Arun Kumar is a Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging/re-emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he worked on the several vaccine development programs based on the messenger RNA technology. He has focused his career on the next-generation platform technologies for vaccine development and translational sciences. At CEPI, he currently leading global preclinical vaccine development programs, and co-leading the CEPI Centralized Global Laboratory Network. He also manages various international collaborative activities.
    Dr. Kumar holds a Ph.D. in Viral Immunology and Infectious diseases from the University of Helsinki, Finland.
     

    Derek O Hagan

    Senior Advisor, GSK
    Derek O Hagan

    Derek O’Hagan, BPharm, MRPharmS, PhD.

    I am currently a Senior Advisor in R&D in GSK Vaccines, since 2018, and a GSK Fellow, since 2019. Prior to this I was the Global Head of Discovery Support and New Technology in GSK Vaccines. Until 2015, I was the Global Head of Vaccine Chemistry and Formulation Research for Novartis Vaccines. I have extensive experience on Vaccine Adjuvants, including participation in the R&D of those included in licensed products and I was part of the Team that established the program on Self Amplifying RNA vaccines (SAM) in Novartis, Cambridge, which is now an active program in GSK. I served on the Board of Scientific Advisors for the Controlled Release Society and I am a Fellow of the American Association of Pharmaceutical Scientists.
     

    Gal Cafri

    Immunotherapy and Genetic Engineering Group leader, Sheba Medical Center
    Gal Cafri

    Dr. Cafri specialized in tumor immunology and cancer immunotherapy. For the last 17 years, Dr. Cafri studies the interactions between tumors and the immune system. He began his career working on chimeric molecules to enhance vaccine activity against skin cancer at the Weizmann Institute of Science. Later on, Dr. Cafri spent 4.5 years at the National Cancer Institute (NCI) in Bethesda, Maryland, specializing in treating patients with immune cells directed against cancer mutations. During his time at the NCI, Dr. Cafri was responsible for developing two clinical trials aiming to vaccinate cancer patients with their tumor mutations. A dendritic cell-based vaccine and a personalized mRNA vaccine in collaboration with Moderna Therapeutics. Dr. Cafri also developed a method to isolate tumor-specific immune cells from patients' blood - a technique that can bypass the need for tumor resection to develop effective cancer immunotherapies. Currently, Dr. Cafri lab at Sheba Medical Center develops T-cell receptor therapy for patients with common epithelial cancers and innovative genetic engineering approaches to introduce genes into human T-cells.

    Heinrich Haas

    Vice President Formulation & Drug Delivery, BioNTech
    Heinrich Haas

    Heinrich has more than 20 years of experience in academic research and industrial pharmaceutical development. His focus is on development for advanced drug delivery systems. After he received his Ph.D. in physical chemistry, he researched lipid membranes and organized biomolecular systems. He was responsible for projects in different biopharmaceutical companies for research and development of diagnostic and therapeutic carrier systems. Joining BioNTech in 2010, he helped build the formulation development and analytics unit, which develops formulations for delivery of RNA and small molecules.

    Priya Karmali

    Vice President, Technology Innovation and Development, Arcturus Therapeutics
    Priya Karmali

    Priya Karmali is Vice President of Technology Innovation and Development at Arcturus Therapeutics. In her current position, she is responsible for research and development efforts for LUNAR® technology, Arcturus’ lipid mediated nucleic acid delivery system. Priya has over 20 years of experience in the field of lipid mediated nucleic acid delivery from discovery to development and has led drug product development of multiple RNA based therapeutics that are currently in various phases of clinical trials. Since joining Arcturus, Priya has led pharmaceutical development efforts for Arcturus’ clinical candidates, LUNAR-OTC (OTC mRNA replacement therapy) and LUNAR-COV19 (COVID-19 Vaccine) and continues to drive similar efforts for upcoming programs in rare diseases and vaccines. Prior to Arcturus, in her role as head of formulation development at Regulus Therapeutics, Priya led drug product development of multiple miRNA candidates currently in clinical trials. Prior to Regulus, Priya held positions of increasing responsibility at Nitto Denko (currently Nitto Biopharma) where she led formulation development efforts for ND-L02-s0201, a Vitamin A targeted siRNA lipid nanoparticle that completed Phase 1b/2 for extensive hepatic fibrosis and currently in Phase 2 evaluation for Idiopathic Pulmonary. Priya received her PhD in Chemistry from the Indian Institute of Chemical Technology, India where her doctoral research was focused on development of novel liposomal nucleic acid delivery systems for use in non-viral gene therapy and DNA vaccination. She pursued her postdoctoral research at Sanford-Burnham-Preby’s-Medical Discovery Institute, La Jolla, CA focusing on developing targeted nanoparticles for drug delivery. Priya is an author and co-inventor on over 40 publications and patents.

    Steve Pascolo

    Founder and CEO, Miescher Pharma GmbH
    Steve Pascolo

    Trained as an immunologist at the Pasteur Institute (Paris, France), Dr. Steve Pascolo used mouse models to test and develop mRNA-based vaccines (direct injection of mRNA) during his post-doc in Tuebingen, Germany from 1998 till 2000. In 2000, he co-founded CureVac with Dr. Hoerr and Dr. von der Mulbe. Dr. Pascolo was Chief Scientific Officer (CSO) of the company from 2000 till 2006, developing the technology, implementing the worldwide first pharmaceutical (GMP) production of mRNA and performing the worldwide first clinical studies where humans (including himself) got injections of in vitro transcribed mRNA. In 2006, he joined the oncology department of the University Hospital of Zurich, Switzerland and continued the development of immunotherapies based on RNA. In 2008, he founded Miescher Pharma to support this work. In 2017, Dr. Pascolo implemented in Zurich an academic mRNA platform https://www.cancer.uzh.ch/en/Research/mRNA-Platform.html. In collaboration with several research and clinical departments in Zurich he optimizes, tests and implements mRNA based vaccines and therapies.

    Sun Woo Hong

    CEO, mCureX Therapeutics
    Sun Woo Hong

    Sun Woo Hong, Ph.D.
    2021. 01 – Present CEO of mCureX Therapeutics, Inc.
    2015. 09 – Present Head of R&D Center at OliX Pharmaceuticals, Inc.
    2010. 09 – 2013. 10 Research professor at Dongguk University, South Korea
    2005. 03 – 2008. 02 Ph.D. in Chemistry at POSTECH, South Korea

    Wigard Kloosterman

    Chief Scientific Officer, Frame Therapeutics
    Wigard Kloosterman

    Dr. Wigard Kloosterman is Chief Scientific Officer at Frame Therapeutics, a biotech start-up aiming at revolutionising cancer immunotherapy based on Framome neoantigen detection technology. Dr. Kloosterman is an expert is cancer genomics and bioinformatics. He has previously served as a group leader at the University Medical Center in Utrecht (Netherlands), where he focused on the analysis of cancer genomes through advanced sequencing technologies. Besides his role at Frame Therapeutics, Dr. Kloosterman founded Cyclomics, a company dedicated to early cancer detection using single-molecule sequencing technology.

    VENUE

    Venue To Be Confirmed

    London, United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Venue To Be Confirmed

    London
    United Kingdom

    Venue To Be Confirmed

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SMi.
    Full details of our privacy policy can be found here https://www.smi-online.co.uk/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smi-online.co.uk.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smi-online.co.uk/opt-out